Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlo Fabris

Showing results (11-20 of 68) with videos related to

Pageof 7
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|March 3, 2007
Valopicitabine dihydrochloride:a specific polymerase inhibitor of hepatitis C virusPierluigi Toniutto, Carlo Fabris, Davide Bitetto, et al.
Digestive Diseases and Sciences|October 21, 2006
The significance of the furosemide test for predicting ascites control by diuretics in cirrhotics: a comparison with volume expansion and octreotide infusionPierluigi Toniutto, Mario Pirisi, Carlo Fabris, et al.
Journal of Hepatology|August 4, 2004
Evaluation of donor hepatic iron concentration as a factor of early fibrotic progression after liver transplantationPierluigi Toniutto, Carlo Fabris, Nadia Bortolotti, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 14, 2005
Low fibrosis progression of recurrent hepatitis C in apolipoprotein E epsilon4 carriers: relationship with the blood lipid profileCarlo Fabris, Pierluigi Toniutto, Davide Bitetto, et al.
Therapeutics and Clinical Risk Management|October 2, 2008
Antiviral treatment in patients with hepatitis C virus-related cirrhosis awaiting liver transplantationPierluigi Toniutto, Carlo Fabris, Davide Bitetto, et al.
Hepatology (Baltimore, Md.)|August 27, 2005
Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferasesCosimo Colletta, Carlo Smirne, Carlo Fabris, et al.
Journal of Gastroenterology|July 27, 2007
Sex-related influence of angiotensin-converting enzyme polymorphisms on fibrosis progression due to recurrent hepatitis C after liver transplantationCarlo Fabris, Pierluigi Toniutto, Davide Bitetto, et al.
Journal of Gastroenterology and Hepatology|January 26, 2011
Apolipoprotein E genotypes modulate fibrosis progression in patients with chronic hepatitis C and persistently normal transaminasesCarlo Fabris, Carmen Vandelli, Pierluigi Toniutto, et al.
Clinical Biochemistry|February 21, 2006
Assessment of liver fibrosis progression in patients with chronic hepatitis C and normal alanine aminotransferase values: the role of AST to the platelet ratio indexCarlo Fabris, Carlo Smirne, Pierluigi Toniutto, et al.
World Journal of Gastroenterology|November 8, 2005
Excess body weight, liver steatosis, and early fibrosis progression due to hepatitis C recurrence after liver transplantationPierluigi Toniutto, Carlo Fabris, Claudio Avellini, et al.
Pageof 7

Showing results (11-20 of 68) with videos related to

Sort By:
Pageof 7
Current Opinion in Investigational Drugs (London, England : 2000)|March 3, 2007
Valopicitabine dihydrochloride:a specific polymerase inhibitor of hepatitis C virusPierluigi Toniutto, Carlo Fabris, Davide Bitetto, et al.
Digestive Diseases and Sciences|October 21, 2006
The significance of the furosemide test for predicting ascites control by diuretics in cirrhotics: a comparison with volume expansion and octreotide infusionPierluigi Toniutto, Mario Pirisi, Carlo Fabris, et al.
Journal of Hepatology|August 4, 2004
Evaluation of donor hepatic iron concentration as a factor of early fibrotic progression after liver transplantationPierluigi Toniutto, Carlo Fabris, Nadia Bortolotti, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 14, 2005
Low fibrosis progression of recurrent hepatitis C in apolipoprotein E epsilon4 carriers: relationship with the blood lipid profileCarlo Fabris, Pierluigi Toniutto, Davide Bitetto, et al.
Therapeutics and Clinical Risk Management|October 2, 2008
Antiviral treatment in patients with hepatitis C virus-related cirrhosis awaiting liver transplantationPierluigi Toniutto, Carlo Fabris, Davide Bitetto, et al.
Hepatology (Baltimore, Md.)|August 27, 2005
Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferasesCosimo Colletta, Carlo Smirne, Carlo Fabris, et al.
Journal of Gastroenterology|July 27, 2007
Sex-related influence of angiotensin-converting enzyme polymorphisms on fibrosis progression due to recurrent hepatitis C after liver transplantationCarlo Fabris, Pierluigi Toniutto, Davide Bitetto, et al.
Journal of Gastroenterology and Hepatology|January 26, 2011
Apolipoprotein E genotypes modulate fibrosis progression in patients with chronic hepatitis C and persistently normal transaminasesCarlo Fabris, Carmen Vandelli, Pierluigi Toniutto, et al.
Clinical Biochemistry|February 21, 2006
Assessment of liver fibrosis progression in patients with chronic hepatitis C and normal alanine aminotransferase values: the role of AST to the platelet ratio indexCarlo Fabris, Carlo Smirne, Pierluigi Toniutto, et al.
World Journal of Gastroenterology|November 8, 2005
Excess body weight, liver steatosis, and early fibrosis progression due to hepatitis C recurrence after liver transplantationPierluigi Toniutto, Carlo Fabris, Claudio Avellini, et al.
Pageof 7